Corbus Pharmaceuticals Holdings, Inc. DEF 14A Filing

TL;DR

<b>Corbus Pharmaceuticals Holdings, Inc. filed its DEF 14A on April 2, 2024, detailing executive compensation adjustments for equity awards.</b>

AI Summary

Corbus Pharmaceuticals Holdings, Inc. (CRBP) filed a Proxy Statement (DEF 14A) with the SEC on April 2, 2024. Corbus Pharmaceuticals Holdings, Inc. filed a DEF 14A form on April 2, 2024. The filing covers the period ending March 29, 2024. The company's principal business address is 500 River Ridge Drive, Norwood, MA 02062. The Standard Industrial Classification code is 2834 (Pharmaceutical Preparations). The filing includes adjustments to compensation for equity awards granted in prior years that were forfeited or vested during the year.

Why It Matters

For investors and stakeholders tracking Corbus Pharmaceuticals Holdings, Inc., this filing contains several important signals. This filing provides transparency into executive compensation, specifically how equity awards granted in previous years are accounted for when forfeited or vested. Investors can analyze these adjustments to understand the impact on executive pay and potential dilution from equity awards.

Risk Assessment

Risk Level: low — Corbus Pharmaceuticals Holdings, Inc. shows low risk based on this filing. The filing is a routine DEF 14A, primarily detailing executive compensation adjustments, which typically carries a low inherent risk.

Analyst Insight

Review the detailed breakdown of equity award adjustments to assess their impact on executive compensation and potential shareholder dilution.

Key Numbers

• 2024-04-02 — Filing Date (DEF 14A)
• 2024-03-29 — Period of Report (DEF 14A)
• 2023-12-31 — Fiscal Year End (Company Data)
• 2013-12-20 — Date of Name Change (Former Company)

Key Players & Entities

• Corbus Pharmaceuticals Holdings, Inc. (company) — Filer
• 0000950170-24-040242 (filing_id) — Accession Number
• 20240402 (date) — Filing Date
• 2834 (sic_code) — Standard Industrial Classification
• 500 River Ridge Drive, Norwood, MA 02062 (address) — Business Address
• SAV Acquisition Corp (company) — Former Company Name

FAQ

Industry Context

Corbus Pharmaceuticals Holdings, Inc. operates in the pharmaceutical preparations industry, focusing on the development of novel therapeutics.

Regulatory Implications

The DEF 14A filing is a standard disclosure required by the SEC for companies soliciting proxies for annual meetings, providing information on executive compensation and corporate governance.

What Investors Should Do

1. Analyze the specific adjustments to equity awards for PEO and Non-PEO members for the years 2021, 2022, and 2023.
2. Examine the fair value calculations and changes in fair value for equity awards granted in prior years.
3. Understand the reasons for forfeitures and vesting of equity awards as detailed in the filing.

Year-Over-Year Comparison

This filing is a DEF 14A, which is a routine disclosure related to executive compensation and shareholder voting, rather than a financial performance report like an 8-K or 10-K.

Key Financial Figures

• $7,500 — ing fee which is not expected to exceed $7,500. We will also, upon request, reimburs

Filing Documents

• crbp-20240329.htm (DEF 14A) — 1166KB
• img115876698_0.jpg (GRAPHIC) — 27KB
• img115876698_1.jpg (GRAPHIC) — 23KB
• img115876698_2.jpg (GRAPHIC) — 47KB
• img115876698_3.jpg (GRAPHIC) — 54KB
• 0000950170-24-040242.txt (&nbsp;) — 2373KB
• crbp-20240329.xsd (EX-101.SCH) — 26KB
• crbp-20240329_htm.xml (XML) — 285KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 16 Summary Compensation Table 16 Employment and Change in Control Agreements 17 Outstanding Equity Awards at December 31, 2023 20 Pay Versus Performance 21 DIRECTOR COMPENSATION 25 EQUITY COMPENSATION PLAN INFORMATION 27 REPORT OF THE AUDIT COMMITTEE 28

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 29 TRANSACTIONS WITH RELATED PERSONS 31 PROPOSAL 2 – APPROVAL OF THE COMPANY'S 2024 EQUITY COMPENSATION PLAN 32 PROPOSAL 3 – RATIFICATION OF THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2024 40 PROPOSAL 4 – APPROVAL, ON AN ADVISORY BASIS, OF THE EXECUTIVE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS 42 STOCKHOLDER PROPOSALS 43 ANNUAL REPORT 44 HOUSEHOLDING OF ANNUAL MEETING MATERIALS 45 OTHER MATTERS 46 APPENDIX A 47 CORBUS PHARMACEUTICALS HOLDINGS, INC. 500 RIVER RIDGE DRIVE NORWOOD, MA 02062 PROXY STATEMENT This proxy statement contains information related to the Annual Meeting of Stockholders (the " Annual Meeting ") of Corbus Pharmaceuticals Holdings, Inc. (the " Company ") to be held on May 16, 2024 at 9:00 a.m. eastern time, or at such other time and place to which the Annual Meeting may be adjourned or postponed. The Annual Meeting will be held live via the internet, at www.virtualstockholdermeeting.com/CRBP2024 . The enclosed proxy is solicited by the Board of Directors of the Company (the " Board "). The proxy materials relating to the Annual Meeting are being mailed to stockholders entitled to vote at the meeting on or about April 3, 2024. A list of record holders of the Company's common stock entitled to vote at the Annual Meeting will be available for examination by any stockholder, for any purpose germane to the Annual Meeting, at our principal offices at 500 River Ridge Drive, Norwood, Massachusetts, 02062, during normal business hours for ten days prior to the Annual Meeting (the " Stockholder List ") and available during the Annual Meeting. ABOUT THE MEETING Why are we calling this Annual Meeting? We are calling the Annual Meeting to seek the approval of our stockholders: To elect eight director nominees to serve as directors until the next annual meeting of stockholders (" Propo

View Full Filing

View this DEF 14A filing on SEC EDGAR